Top 5 Stocks to Buy Now
→ Solar is dead. Here’s what replaces it. (From Behind the Markets) (Ad)tc pixel Free BPCR Stock Alerts

BioPharma Credit (BPCR) Competitors

BioPharma Credit logo
GBX 0.96 0.00 (-0.21%)
As of 12:06 PM Eastern
Compare

BPCR vs. LGT, RIV, SGEM, NBMI, and ASIZ

Should you buy BioPharma Credit stock or one of its competitors? MarketBeat compares BioPharma Credit with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with BioPharma Credit include Lighthouse Group (LGT), River and Mercantile Group (RIV), ScotGems (SGEM), NB Global Monthly Income Fund Ltd GBP (NBMI), and Aberforth Split Level Income ZDP 2024 (ASIZ). These companies are all part of the "asset management" industry.

How does BioPharma Credit compare to Lighthouse Group?

BioPharma Credit (LON:BPCR) and Lighthouse Group (LON:LGT) are both small-cap asset management industry companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, profitability, earnings, dividends, valuation, risk and institutional ownership.

BioPharma Credit has higher revenue and earnings than Lighthouse Group. Lighthouse Group is trading at a lower price-to-earnings ratio than BioPharma Credit, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BioPharma Credit£132.06M0.08£10.42B£11.400.08
Lighthouse Group£53.42M0.00N/A£1.80N/A

In the previous week, BioPharma Credit's average media sentiment score of 0.00 equaled Lighthouse Group'saverage media sentiment score.

Company Overall Sentiment
BioPharma Credit Neutral
Lighthouse Group Neutral

BioPharma Credit pays an annual dividend of GBX 7 per share and has a dividend yield of 727.7%. Lighthouse Group pays an annual dividend of GBX 0.01 per share. BioPharma Credit pays out 61.4% of its earnings in the form of a dividend. Lighthouse Group pays out 0.6% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years.

BioPharma Credit has a net margin of 92.62% compared to Lighthouse Group's net margin of 0.00%. BioPharma Credit's return on equity of 11.29% beat Lighthouse Group's return on equity.

Company Net Margins Return on Equity Return on Assets
BioPharma Credit92.62% 11.29% 4.98%
Lighthouse Group N/A N/A N/A

31.7% of BioPharma Credit shares are held by institutional investors. 0.1% of BioPharma Credit shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

BioPharma Credit beats Lighthouse Group on 8 of the 10 factors compared between the two stocks.

How does BioPharma Credit compare to River and Mercantile Group?

BioPharma Credit (LON:BPCR) and River and Mercantile Group (LON:RIV) are both small-cap asset management industry companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, profitability, analyst recommendations, media sentiment, dividends, institutional ownership, valuation and risk.

BioPharma Credit has higher revenue and earnings than River and Mercantile Group. River and Mercantile Group is trading at a lower price-to-earnings ratio than BioPharma Credit, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BioPharma Credit£132.06M0.08£10.42B£11.400.08
River and Mercantile Group£74.82M0.00N/A-£2.20N/A

BioPharma Credit pays an annual dividend of GBX 7 per share and has a dividend yield of 727.7%. River and Mercantile Group pays an annual dividend of GBX 0.09 per share. BioPharma Credit pays out 61.4% of its earnings in the form of a dividend. River and Mercantile Group pays out -4.1% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years.

In the previous week, BioPharma Credit's average media sentiment score of 0.00 equaled River and Mercantile Group'saverage media sentiment score.

Company Overall Sentiment
BioPharma Credit Neutral
River and Mercantile Group Neutral

31.7% of BioPharma Credit shares are owned by institutional investors. 0.1% of BioPharma Credit shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

BioPharma Credit has a net margin of 92.62% compared to River and Mercantile Group's net margin of 0.00%. BioPharma Credit's return on equity of 11.29% beat River and Mercantile Group's return on equity.

Company Net Margins Return on Equity Return on Assets
BioPharma Credit92.62% 11.29% 4.98%
River and Mercantile Group N/A N/A N/A

Summary

BioPharma Credit beats River and Mercantile Group on 9 of the 10 factors compared between the two stocks.

How does BioPharma Credit compare to ScotGems?

BioPharma Credit (LON:BPCR) and ScotGems (LON:SGEM) are both small-cap asset management industry companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, valuation, analyst recommendations, earnings, risk, institutional ownership, profitability and dividends.

31.7% of BioPharma Credit shares are owned by institutional investors. 0.1% of BioPharma Credit shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

BioPharma Credit has a net margin of 92.62% compared to ScotGems' net margin of 0.00%. BioPharma Credit's return on equity of 11.29% beat ScotGems' return on equity.

Company Net Margins Return on Equity Return on Assets
BioPharma Credit92.62% 11.29% 4.98%
ScotGems N/A N/A N/A

BioPharma Credit pays an annual dividend of GBX 7 per share and has a dividend yield of 727.7%. ScotGems pays an annual dividend of GBX 4 per share. BioPharma Credit pays out 61.4% of its earnings in the form of a dividend. ScotGems pays out 5,714.3% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. BioPharma Credit is clearly the better dividend stock, given its higher yield and lower payout ratio.

In the previous week, BioPharma Credit's average media sentiment score of 0.00 equaled ScotGems'average media sentiment score.

Company Overall Sentiment
BioPharma Credit Neutral
ScotGems Neutral

BioPharma Credit has higher revenue and earnings than ScotGems. ScotGems is trading at a lower price-to-earnings ratio than BioPharma Credit, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BioPharma Credit£132.06M0.08£10.42B£11.400.08
ScotGems£5.07M0.00N/A£0.07N/A

Summary

BioPharma Credit beats ScotGems on 9 of the 10 factors compared between the two stocks.

How does BioPharma Credit compare to NB Global Monthly Income Fund Ltd GBP?

NB Global Monthly Income Fund Ltd GBP (LON:NBMI) and BioPharma Credit (LON:BPCR) are both small-cap financial services companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, valuation, institutional ownership, earnings, profitability, dividends, media sentiment and analyst recommendations.

BioPharma Credit has higher revenue and earnings than NB Global Monthly Income Fund Ltd GBP. NB Global Monthly Income Fund Ltd GBP is trading at a lower price-to-earnings ratio than BioPharma Credit, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
NB Global Monthly Income Fund Ltd GBPN/AN/AN/A£0.17N/A
BioPharma Credit£132.06M0.08£10.42B£11.400.08

44.3% of NB Global Monthly Income Fund Ltd GBP shares are held by institutional investors. Comparatively, 31.7% of BioPharma Credit shares are held by institutional investors. 0.2% of NB Global Monthly Income Fund Ltd GBP shares are held by insiders. Comparatively, 0.1% of BioPharma Credit shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

NB Global Monthly Income Fund Ltd GBP pays an annual dividend of GBX 9 per share. BioPharma Credit pays an annual dividend of GBX 7 per share and has a dividend yield of 727.7%. NB Global Monthly Income Fund Ltd GBP pays out 5,294.1% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. BioPharma Credit pays out 61.4% of its earnings in the form of a dividend. BioPharma Credit is clearly the better dividend stock, given its higher yield and lower payout ratio.

BioPharma Credit has a net margin of 92.62% compared to NB Global Monthly Income Fund Ltd GBP's net margin of 0.00%. BioPharma Credit's return on equity of 11.29% beat NB Global Monthly Income Fund Ltd GBP's return on equity.

Company Net Margins Return on Equity Return on Assets
NB Global Monthly Income Fund Ltd GBPN/A N/A N/A
BioPharma Credit 92.62%11.29%4.98%

In the previous week, NB Global Monthly Income Fund Ltd GBP's average media sentiment score of 0.00 equaled BioPharma Credit'saverage media sentiment score.

Company Overall Sentiment
NB Global Monthly Income Fund Ltd GBP Neutral
BioPharma Credit Neutral

Summary

BioPharma Credit beats NB Global Monthly Income Fund Ltd GBP on 7 of the 10 factors compared between the two stocks.

How does BioPharma Credit compare to Aberforth Split Level Income ZDP 2024?

BioPharma Credit (LON:BPCR) and Aberforth Split Level Income ZDP 2024 (LON:ASIZ) are both small-cap asset management industry companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, institutional ownership, risk, profitability, media sentiment, valuation, analyst recommendations and earnings.

31.7% of BioPharma Credit shares are owned by institutional investors. Comparatively, 39.2% of Aberforth Split Level Income ZDP 2024 shares are owned by institutional investors. 0.1% of BioPharma Credit shares are owned by insiders. Comparatively, 0.0% of Aberforth Split Level Income ZDP 2024 shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

BioPharma Credit has a beta of 0.22126153, meaning that its share price is 78% less volatile than the broader market. Comparatively, Aberforth Split Level Income ZDP 2024 has a beta of 1.67, meaning that its share price is 67% more volatile than the broader market.

BioPharma Credit has higher revenue and earnings than Aberforth Split Level Income ZDP 2024. Aberforth Split Level Income ZDP 2024 is trading at a lower price-to-earnings ratio than BioPharma Credit, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BioPharma Credit£132.06M0.08£10.42B£11.400.08
Aberforth Split Level Income ZDP 2024£821K0.00N/A-£2.80N/A

In the previous week, BioPharma Credit's average media sentiment score of 0.00 equaled Aberforth Split Level Income ZDP 2024'saverage media sentiment score.

Company Overall Sentiment
BioPharma Credit Neutral
Aberforth Split Level Income ZDP 2024 Neutral

BioPharma Credit has a net margin of 92.62% compared to Aberforth Split Level Income ZDP 2024's net margin of -104.99%. BioPharma Credit's return on equity of 11.29% beat Aberforth Split Level Income ZDP 2024's return on equity.

Company Net Margins Return on Equity Return on Assets
BioPharma Credit92.62% 11.29% 4.98%
Aberforth Split Level Income ZDP 2024 -104.99%-0.49%-0.30%

Summary

BioPharma Credit beats Aberforth Split Level Income ZDP 2024 on 7 of the 9 factors compared between the two stocks.

Get BioPharma Credit News Delivered to You Automatically

Sign up to receive the latest news and ratings for BPCR and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

BPCR vs. The Competition

Export
MetricBioPharma CreditAsset Management IndustryFinancial SectorLON Exchange
Market Cap£10.80M£2.42B£6.01B£2.77B
Dividend Yield7.34%6.03%5.26%6.16%
P/E Ratio0.0825.7316.20366.61
Price / Sales0.082,047.331,454.1786,103.13
Price / Cash1.1960.3385.1427.87
Price / Book0.011.386.657.85
Net Income£10.42B£265.27M£1.14B£5.89B
7 Day Performance1.05%-0.61%-0.50%-0.97%
1 Month Performance1.26%-0.25%0.69%-0.79%
1 Year Performance7.85%9.52%19.23%68.88%

BioPharma Credit Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
BPCR
BioPharma Credit
N/AGBX 0.96
-0.2%		N/A+7.6%£10.80M£132.06M0.08N/A
LGT
Lighthouse Group
N/AN/AN/AN/A£42.46M£53.42M18.47156
RIV
River and Mercantile Group
N/AN/AN/AN/A£42.40M£74.82MN/A300
SGEM
ScotGems
N/AN/AN/AN/A£42.02M£5.07M1,121.43N/A
NBMI
NB Global Monthly Income Fund Ltd GBP
N/AN/AN/AN/A£41.02MN/A338.24N/A

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (LON:BPCR) was last updated on 6/24/2026 by MarketBeat.com Staff.
From Our Partners
Firm That Predicted 2008, 2020, 2022: Right Now Looks Worse
The firm that predicted the dot-com crash, the 2008 financial crisis, the 2020 COVID crash, and the 2022 bear ...
TradeSmith | Sponsoredtc pixel
The Treasury just bought its own debt
On April 16th, the U.S. Treasury executed a $15 billion buyback of its own debt - the largest in history - whi...
Golden Portfolio | Sponsoredtc pixel
BlackRock is hoarding it. JPMorgan is hoarding it. Do you own it?
BlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...
Awesomely, LLC | Sponsoredtc pixel
Buy this stock today
Marc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to mo...
Chaikin Analytics | Sponsoredtc pixel
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
PH: Do THESE 4 things to your bank account now …
In a few short months, the US government could gain unprecedented powers over personal bank accounts - includi...
Weiss Ratings | Sponsoredtc pixel
VWAV: An Under-the-Radar Defense Play
VisionWave Holdings (NASDAQ: VWAV) is developing a multi-domain defense platform combining AI-powered analytic...
Equiscreen | Sponsoredtc pixel
The fastest-growing business in capitalism's history
While investors were focused on the SpaceX IPO, Elon Musk quietly began backing a new AI startup - one that's ...
Brownstone Research | Sponsoredtc pixel